PDCD1 and lung carcinoma: We found that RSL treatment could significantly increase ferroptosis in tumors and reduce the growth rate and weight of tumors in vivo, which is consistent with a previous study in a syngeneic 4T1 mouse model and in lung cancer patients.33 Therefore, RLS may be a promising drug to enhance the efficacy of anti-PD-1 treatment in CRC patients.